Mangalam Drugs & Organics Limited (MANGALAM.BO)
INR 75.87
(4.16%)
INR 75.87
(4.16%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 703.6 Million INR | 0.3% |
| 2022 | 701.5 Million INR | -28.96% |
| 2021 | 987.42 Million INR | 1.1% |
| 2020 | 976.68 Million INR | 54.8% |
| 2019 | 630.91 Million INR | 32.72% |
| 2018 | 475.36 Million INR | -45.15% |
| 2017 | 866.59 Million INR | 1.41% |
| 2016 | 854.56 Million INR | 30.78% |
| 2015 | 653.45 Million INR | 60.02% |
| 2014 | 408.35 Million INR | 54.2% |
| 2013 | 264.81 Million INR | 136.69% |
| 2012 | 111.88 Million INR | -63.33% |
| 2011 | 305.07 Million INR | 18.09% |
| 2010 | 258.34 Million INR | 71.48% |
| 2009 | 150.65 Million INR | 16.1% |
| 2008 | 129.76 Million INR | 32.02% |
| 2007 | 98.29 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 226.8 Million INR | -20.72% |
| 2023 Q1 | 211.31 Million INR | 180.38% |
| 2023 FY | 703.6 Million INR | 0.3% |
| 2023 Q4 | 286.07 Million INR | 84.91% |
| 2023 Q3 | 154.71 Million INR | -49.52% |
| 2023 Q2 | 306.48 Million INR | 45.03% |
| 2022 Q3 | 299.59 Million INR | -8.42% |
| 2022 FY | 701.5 Million INR | -28.96% |
| 2022 Q4 | -262.88 Million INR | -187.75% |
| 2022 Q1 | 355.3 Million INR | 314.51% |
| 2022 Q2 | 327.14 Million INR | -7.93% |
| 2021 Q2 | 339.3 Million INR | 15.03% |
| 2021 Q4 | 85.71 Million INR | -68.1% |
| 2021 Q1 | 294.96 Million INR | 2822.34% |
| 2021 Q3 | 268.69 Million INR | -20.81% |
| 2021 FY | 987.42 Million INR | 1.1% |
| 2020 Q1 | 306.11 Million INR | 5535.33% |
| 2020 FY | 976.68 Million INR | 54.8% |
| 2020 Q3 | 323.6 Million INR | -10.32% |
| 2020 Q4 | -10.83 Million INR | -103.35% |
| 2020 Q2 | 360.85 Million INR | 17.88% |
| 2019 FY | 630.91 Million INR | 32.72% |
| 2019 Q1 | 210.92 Million INR | 248.59% |
| 2019 Q4 | 5.43 Million INR | -97.34% |
| 2019 Q2 | 210.4 Million INR | -0.24% |
| 2019 Q3 | 204.16 Million INR | -2.97% |
| 2018 FY | 475.36 Million INR | -45.15% |
| 2018 Q4 | -141.94 Million INR | -183.94% |
| 2018 Q3 | 169.1 Million INR | -28.86% |
| 2018 Q2 | 237.69 Million INR | 12.92% |
| 2018 Q1 | 210.5 Million INR | -20.75% |
| 2017 Q3 | 280.51 Million INR | -12.13% |
| 2017 Q2 | 319.23 Million INR | 8.29% |
| 2017 FY | 866.59 Million INR | 1.41% |
| 2017 Q1 | 294.79 Million INR | 0.01% |
| 2017 Q4 | 265.62 Million INR | -5.31% |
| 2016 Q2 | 244.85 Million INR | 8.05% |
| 2016 Q1 | 226.62 Million INR | 605.7% |
| 2016 Q4 | 294.77 Million INR | 1.88% |
| 2016 FY | 854.56 Million INR | 30.78% |
| 2016 Q3 | 289.33 Million INR | 18.17% |
| 2015 Q1 | 182.76 Million INR | 7880.83% |
| 2015 Q2 | 236.34 Million INR | 29.32% |
| 2015 FY | 653.45 Million INR | 60.02% |
| 2015 Q4 | 32.11 Million INR | -84.59% |
| 2015 Q3 | 208.45 Million INR | -11.8% |
| 2014 Q2 | 133.54 Million INR | 7.5% |
| 2014 Q3 | 148.3 Million INR | 11.05% |
| 2014 FY | 408.35 Million INR | 54.2% |
| 2014 Q4 | 2.29 Million INR | -98.46% |
| 2014 Q1 | 124.22 Million INR | 478.33% |
| 2013 Q1 | 43.39 Million INR | 175.37% |
| 2013 Q2 | 114.05 Million INR | 162.86% |
| 2013 FY | 264.81 Million INR | 136.69% |
| 2013 Q4 | -32.83 Million INR | -123.67% |
| 2013 Q3 | 138.73 Million INR | 21.64% |
| 2012 Q1 | 34.79 Million INR | 140.95% |
| 2012 FY | 111.88 Million INR | -63.33% |
| 2012 Q4 | -57.57 Million INR | -162.77% |
| 2012 Q3 | 91.71 Million INR | 58.21% |
| 2012 Q2 | 57.97 Million INR | 66.59% |
| 2011 FY | 305.07 Million INR | 18.09% |
| 2011 Q4 | -84.97 Million INR | -172.26% |
| 2011 Q3 | 117.58 Million INR | 0.0% |
| 2010 FY | 258.34 Million INR | 71.48% |
| 2009 FY | 150.65 Million INR | 16.1% |
| 2008 FY | 129.76 Million INR | 32.02% |
| 2007 FY | 98.29 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.373% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.545% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 94.341% |
| Granules India Limited | 16.79 Billion INR | 95.812% |
| Indoco Remedies Limited | 6.04 Billion INR | 88.353% |
| Achyut Healthcare Limited | 4.86 Million INR | -14374.491% |
| Ajanta Pharma Limited | 21.06 Billion INR | 96.66% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.655% |
| Alpa Laboratories Limited | 188.89 Million INR | -272.485% |
| Brooks Laboratories Limited | 65.62 Million INR | -972.242% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 88.693% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 52.194% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 80.96% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.57% |
| Eris Lifesciences Limited | 10.42 Billion INR | 93.252% |
| FDC Limited | 8.33 Billion INR | 91.558% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.985% |
| Gufic Biosciences Limited | 4.16 Billion INR | 83.118% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 88.641% |
| Ipca Laboratories Limited | 29.8 Billion INR | 97.64% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -7.817% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -265.079% |
| Lasa Supergenerics Limited | 121.02 Million INR | -481.348% |
| Laurus Labs Limited | 24.62 Billion INR | 97.142% |
| Lupin Limited | 123.71 Billion INR | 99.431% |
| Mankind Pharma Limited | 44.52 Billion INR | 98.42% |
| Medicamen Biotech Limited | 495.49 Million INR | -42.0% |
| Medico Remedies Limited | 262.14 Million INR | -168.404% |
| Megasoft Limited | 342.07 Million INR | -105.69% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.266% |
| Piramal Pharma Limited | 24.47 Billion INR | 97.125% |
| RPG Life Sciences Limited | 2.48 Billion INR | 71.663% |
| Sigachi Industries Limited | 2 Billion INR | 64.86% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.728% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 82.936% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 25.339% |
| Unichem Laboratories Limited | 4.86 Billion INR | 85.537% |
| Wanbury Limited | 1.73 Billion INR | 59.344% |
| Windlas Biotech Limited | 1.33 Billion INR | 47.445% |
| ZIM Laboratories Limited | 1.26 Billion INR | 44.462% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.438% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 216.799% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.831% |
| Hester Biosciences Limited | 1.27 Billion INR | 44.757% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 87.83% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 54.797% |
| Bal Pharma Limited | 770.19 Million INR | 8.646% |
| Strides Pharma Science Limited | 14.38 Billion INR | 95.11% |
| Venus Remedies Limited | 2.18 Billion INR | 67.763% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 87.934% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 76.326% |
| Shilpa Medicare Limited | 3.54 Billion INR | 80.163% |
| Aarti Drugs Limited | 8.31 Billion INR | 91.539% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 84.64% |
| Suven Life Sciences Limited | -200.79 Million INR | 450.406% |
| Ind-Swift Limited | 2.17 Billion INR | 67.614% |
| Valiant Laboratories Limited | -60.66 Million INR | 1259.839% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 96.9% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 18.299% |
| Themis Medicare Limited | 1.5 Billion INR | 53.215% |
| Hikal Limited | 3.14 Billion INR | 77.614% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.495% |
| Sequent Scientific Limited | 2.97 Billion INR | 76.379% |
| Novartis India Limited | 1.32 Billion INR | 46.974% |
| Wockhardt Limited | 16.24 Billion INR | 95.667% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 96.418% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -4725.922% |
| Neuland Laboratories Limited | 8.24 Billion INR | 91.469% |
| Morepen Laboratories Limited | 6.16 Billion INR | 88.58% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -13.397% |